Copyright
©The Author(s) 2019.
World J Gastroenterol. Aug 7, 2019; 25(29): 4007-4018
Published online Aug 7, 2019. doi: 10.3748/wjg.v25.i29.4007
Published online Aug 7, 2019. doi: 10.3748/wjg.v25.i29.4007
Table 2 Primary endpoint: dermatological toxicities (primary analysis set, n = 229)
| Day 15 (n = 214) | Month 1 (n = 208) | Month 2 (n = 186) | Month 3 (n = 153) | Month 4 (n = 122) | Month 5 (n = 93) | Month 6 (n = 87) | |
| At least one dermatological toxicity, n (%) | 127 (59.3) | 141 (67.8) | 139 (74.7) | 107 (69.9) | 76 (63.3) | 52 (57.1) | 40 (46.5) |
| Dermatological toxicities | |||||||
| Rash/acneiform rash, n (%) | 111 (51.9) | 123 (59.1) | 110 (59.1) | 85 (55.6) | 56 (45.9) | 41 (44.1) | 34 (39.1) |
| Grade 1-2 | 101 (47.2) | 115 (55.3) | 99 (53.2) | 82 (53.6) | 51 (41.8) | 39 (41.9) | 33 (37.9) |
| Grade 3-4 | 10 (4.7) | 7 (3.4) | 8 (4.3) | 2 (1.1) | 4 (3.2) | 1 (1.1) | 1 (1.1) |
| Grade missing | 0 | 1 | 3 | 1 | 1 | 1 | 0 |
| Skin cracks, n (%) | 5 (2.3) | 17 (8.2) | 35 (18.8) | 34 (22.2) | 23 (18.9) | 20 (21.5) | 17 (19.5) |
| Grade 1-2 | 4 (1.9) | 16 (7.7) | 32 (17.2) | 33 (21.6) | 22 (18.0) | 19 (20.4) | 17 (19.8) |
| Grade 3-4 | 1 (0.5) | 1 (0.5) | 3 (1.6) | 1 (0.6) | 1 (0.8) | 0 | 0 |
| Grade missing | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
| Paronychia/Perionyxis, n (%) | 6 (2.8) | 11 (5.3) | 22 (11.8) | 15 (9.8) | 12 (9.8) | 9 (9.7) | 5 (5.7) |
| Grade 1-2 | 6 (2.8) | 10 (4.8) | 21 (11.3) | 15 (9.8) | 12 (9.8) | 8 (8.6) | 5 (5.7) |
| Grade 3-4 | 0 | 1 (0.5) | 1 (0.5) | 0 | 0 | 1 (1.1) | 0 |
| Xerosis, n (%) | 27 (12.6) | 36 (17.3) | 53 (28.5) | 44 (28.8) | 22 (18.0) | 15 (16.1) | 11 (12.6) |
| Grade 1-2 | 27 (12.6) | 34 (16.3) | 51 (27.4) | 43 (28.1) | 21 (17.2) | 15 (16.1) | 11 (12.6) |
| Grade 3-4 | 0 | 2 (1.0) | 2 (1.1) | 0 | 1 (0.8) | 0 | 0 |
| Grade missing | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| Mucositis, n (%) | 12 (5.6) | 15 (7.2) | 19 (10.2) | 8 (5.2) | 3 (2.5) | 3 (3.2) | 2 (2.3) |
| Grade 1-2 | 12 (5.6) | 15 (7.2) | 18 (9.7) | 8 (5.2) | 3 (2.5) | 3 (3.2) | 2 (2.3) |
| Grade 3-4 | 0 | 0 | 1 (0.5) | 0 | 0 | 0 | 0 |
| Hypertrichosis, n (%) | 1 (0.5) | 4 (1.9) | 5 (2.7) | 7 (4.6) | 7 (5.7) | 2 (2.2) | 2 (2.3) |
| Grade 1-2 | 1 (0.5) | 4 (1.9) | 5 (2.7) | 7 (4.6) | 7 (5.7) | 2 (2.2) | 2 (2.3) |
| Other, n (%) | 5 (2.3) | 5 (2.4) | 4 (2.2) | 4 (2.6) | 3 (2.5) | 0 | 1 (1.1) |
| Grade 1-2 | 5 (2.3) | 5 (2.4) | 4 (2.2) | 4 (2.6) | 3 (2.5) | 0 | 1 (1.1) |
- Citation: Bouché O, Ben Abdelghani M, Labourey JL, Triby S, Bensadoun RJ, Jouary T, Des Guetz G. Management of skin toxicities during panitumumab treatment in metastatic colorectal cancer. World J Gastroenterol 2019; 25(29): 4007-4018
- URL: https://www.wjgnet.com/1007-9327/full/v25/i29/4007.htm
- DOI: https://dx.doi.org/10.3748/wjg.v25.i29.4007